Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 14c

November 9, 2016 7:06 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.70), $0.14 better than the analyst estimate of ($0.84). Revenue for the quarter came in at $4.36 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

The Children's Investment Fund (TCI), Earnings